H. Mutlu Et Al. , "Docetaxel plus cisplatin plus fluorouracil versus carboplatin plus fluorouracil-cetuximab in first-line setting in patients with recurrent or metastatic head and neck squamous cell cancer who did not previously receive neoadjuvant or adjuvant chemotherapy, which is standard?," JOURNAL OF CANCER RESEARCH AND THERAPEUTICS , vol.13, no.3, pp.510-513, 2017
Mutlu, H. Et Al. 2017. Docetaxel plus cisplatin plus fluorouracil versus carboplatin plus fluorouracil-cetuximab in first-line setting in patients with recurrent or metastatic head and neck squamous cell cancer who did not previously receive neoadjuvant or adjuvant chemotherapy, which is standard?. JOURNAL OF CANCER RESEARCH AND THERAPEUTICS , vol.13, no.3 , 510-513.
Mutlu, H., Salim, D. K., Gunduz, S., Eryilmaz, M. K., Musri, F. Y., & COŞKUN, H. Ş., (2017). Docetaxel plus cisplatin plus fluorouracil versus carboplatin plus fluorouracil-cetuximab in first-line setting in patients with recurrent or metastatic head and neck squamous cell cancer who did not previously receive neoadjuvant or adjuvant chemotherapy, which is standard?. JOURNAL OF CANCER RESEARCH AND THERAPEUTICS , vol.13, no.3, 510-513.
Mutlu, HASAN Et Al. "Docetaxel plus cisplatin plus fluorouracil versus carboplatin plus fluorouracil-cetuximab in first-line setting in patients with recurrent or metastatic head and neck squamous cell cancer who did not previously receive neoadjuvant or adjuvant chemotherapy, which is standard?," JOURNAL OF CANCER RESEARCH AND THERAPEUTICS , vol.13, no.3, 510-513, 2017
Mutlu, HASAN Et Al. "Docetaxel plus cisplatin plus fluorouracil versus carboplatin plus fluorouracil-cetuximab in first-line setting in patients with recurrent or metastatic head and neck squamous cell cancer who did not previously receive neoadjuvant or adjuvant chemotherapy, which is standard?." JOURNAL OF CANCER RESEARCH AND THERAPEUTICS , vol.13, no.3, pp.510-513, 2017
Mutlu, H. Et Al. (2017) . "Docetaxel plus cisplatin plus fluorouracil versus carboplatin plus fluorouracil-cetuximab in first-line setting in patients with recurrent or metastatic head and neck squamous cell cancer who did not previously receive neoadjuvant or adjuvant chemotherapy, which is standard?." JOURNAL OF CANCER RESEARCH AND THERAPEUTICS , vol.13, no.3, pp.510-513.
@article{article, author={HASAN MUTLU Et Al. }, title={Docetaxel plus cisplatin plus fluorouracil versus carboplatin plus fluorouracil-cetuximab in first-line setting in patients with recurrent or metastatic head and neck squamous cell cancer who did not previously receive neoadjuvant or adjuvant chemotherapy, which is standard?}, journal={JOURNAL OF CANCER RESEARCH AND THERAPEUTICS}, year=2017, pages={510-513} }